<DOC>
	<DOC>NCT00435487</DOC>
	<brief_summary>To compare efficacy and safety of dalteparin compared to unfractionated heparin in patients of non ST elevation acute coronary syndromes who are planned to undergo coronary interventions (angioplasty or bypass surgery)</brief_summary>
	<brief_title>Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome</brief_title>
	<detailed_description>The study was prematurely discontinued on November 30, 2008 due to delay in meeting pre-defined protocol recruitment milestones. There were no safety concerns regarding the study in the decision to terminate the trial.</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina, Unstable</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<criteria>Patients more than 18 years Ischemic pain of more than 10 minutes within 24 hours before enrollment At least two of the following three risk factors : Age more than 60 years ( or more than 50 in case of diabetics), Raised cardiac enzyme levels, abnormal ECG findings Contraindications to use of anticoagulants Active bleeding or abnormal coagulation tests Ischemic stroke within last 6 months or hemorrhagic stroke Lumbar or spinal puncture within last 48 hours S creatinine levels more than 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Non-ST Elevation Acute Coronary Syndromes coronary interventions</keyword>
</DOC>